Trial Profile

A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary) ; Rituximab (Primary) ; Prednisolone
Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis; Microscopic polyangiitis
Focus Pharmacodynamics
Acronyms COMBIVAS

Most Recent Events

11 Mar 2023 Trial design published in the Trials
21 Feb 2022 Planned End Date changed from 1 Feb 2023 to 1 Nov 2023.
21 Feb 2022 Planned primary completion date changed from 1 Feb 2023 to 1 Apr 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com